Trial Profile
Post-marketing study of Remsima in patients from South Korea with inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- 30 Oct 2015 New trial record
- 27 Oct 2015 Results published in the Expert Review of Gastroenterology and Hepatology, according to Celltrion media release.